spacer
home > ict > autumn 2016 > are you mobile?
PUBLICATIONS
International Clinical Trials

Are You Mobile?

Over the past five years, there has been an explosion of IT in the healthcare sector. One facet of this boom is mobile health (mHealth), which is defined as any patient health information accessed using mobile technology – such as a smartphone, tablet or any other wireless device. The industry is quickly learning how to deploy this relatively new medium to deal with difficulties and improve workflows for doctors and patients alike.

The growing utilisation of mobiles is inevitable. Current estimates show that there are 3.8 billion mobile device owners, which is a penetration rate of 51% globally – though there are obviously differences from country to country. In Spain, for instance, 87% of the population possesses a mobile device, while only 52% of people living in India own one.

This huge expansion of mobiles into the market has also occurred with alarming speed. The mobile’s share of global web traffic in 2009 was less than 1%. Over the course of 6-7 years, that number has erupted to almost 40% of all web traffic for 2016. Those numbers are hard to ignore.

The prevalence and use of mobile technology has caused a recent flood of new mHealth apps, with more than 165,000 available online (1). For us, the question is how and when do we incorporate mobile devices into a clinical trial?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Executive Director, Nancy Mulligan leads the team at UBC’s Patient and Physician Services and manages strategy, business planning and health technology solutions that support patients in the commercial or clinical setting. She has more than 20 years of experience in the pharmaceutical industry, with expertise in patient and doctor recruitment.

As Senior Web Designer for UBC’s Patient and Physician Services, Patrick Prugh is responsible for designing and developing patient recruitment and retention websites. He has 15 years of experience working in multimedia and creative services, and has won multiple awards for his work – including an ADDY award in 2008 and a POLLIE award in 2010.

spacer
Nancy Mulligan
spacer
spacer
spacer
Patrick Prugh
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IMFINZITM (durvalumab) WITH CHEMOTHERAPY DEMONSTRATED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN THE PHASE III CASPIAN TRIAL

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement